BeOne Medicines Ltd. – Sponsored ADR $ONC Stock Holdings Decreased by Primecap Management Co. CA

Primecap Management Co. CA lessened its position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 0.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,080,461 shares of the company’s stock after selling 7,818 shares during the quarter. BeOne Medicines makes up about 1.3% of Primecap Management Co. CA’s holdings, making the stock its 21st biggest holding. Primecap Management Co. CA owned 4.63% of BeOne Medicines worth $1,730,913,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Temasek Holdings Private Ltd acquired a new stake in BeOne Medicines during the 2nd quarter valued at $244,603,000. Marshall Wace LLP acquired a new stake in shares of BeOne Medicines in the second quarter worth $113,190,000. Baird Financial Group Inc. purchased a new position in shares of BeOne Medicines during the second quarter valued at $82,895,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in BeOne Medicines during the second quarter valued at $73,347,000. Finally, Candriam S.C.A. purchased a new stake in BeOne Medicines in the 2nd quarter worth about $67,852,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Price Performance

NASDAQ ONC opened at $351.92 on Thursday. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $38.59 billion, a PE ratio of 690.04 and a beta of 0.52. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $196.45 and a 12-month high of $385.22. The company has a 50 day moving average price of $336.49 and a two-hundred day moving average price of $330.27.

Insiders Place Their Bets

In other BeOne Medicines news, CEO John Oyler sold 75,631 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $307.79, for a total transaction of $23,278,465.49. Following the transaction, the chief executive officer directly owned 24,369 shares in the company, valued at $7,500,534.51. This trade represents a 75.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Chan Henry Lee sold 1,660 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total value of $580,203.20. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 102,656 shares of company stock worth $31,567,496 in the last 90 days. 6.62% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ONC. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, January 21st. Citigroup boosted their price objective on shares of BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Truist Financial set a $400.00 target price on shares of BeOne Medicines in a research report on Monday, November 24th. Barclays lifted their target price on shares of BeOne Medicines from $385.00 to $394.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $420.00 price target on shares of BeOne Medicines in a research note on Monday, November 17th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BeOne Medicines presently has an average rating of “Moderate Buy” and an average price target of $381.46.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.